Watch: Transforming animal medicines: the science explained.

Biologics have transformed human medicine in recent decades. Now, Nexvet aims to be a global leader in veterinary biologics.

Overview

Biologics are therapeutic proteins, which have transformed human medicine in recent decades thanks to advances in biotechnology. They are distinct from chemically synthesized small molecule pharmaceuticals. Biologics include major categories such as mAbs, receptor fusion proteins and hormone therapies.

We believe we are the only clinical stage animal health company completely focused on bringing a 100% species-specific biologics portfolio to market.

Biologics in human medicine

In human medicine, the introduction of biologics, specifically mAbs, overcame many issues associated with small molecule-based therapeutics, and have now grown to be the largest class of therapeutics within the top ten best-selling drugs in humans. Six of 2013’s top ten best-selling human drugs were biologics (5 mAbs and one fusion protein), which collectively amounted to worldwide sales in 2013 of $49.1 billion. We believe that mAbs will drive a similar trend in the companion animal therapeutics market.

I work in animal healthcare, and I would like to be kept updated on Nexvet's clinical development progress, as well as receiving more information on veterinary biologics and educational opportunities:



Captcha Code

Click the image to see another captcha.

The opportunity in veterinary medicine

There has been very limited activity in therapeutic veterinary biologics compared to human medicine, with only a small number of marketing approvals issued in the U.S. or EU. We believe this creates a significant opportunity for us to develop first-in-class therapeutics for the unmet medical needs of companion animals utilizing our proprietary PETization platform. We believe a number of factors have prevented mAbs from reaching the animal health market, which PETization can address:

    • Research and development priorities. We believe that constrained research and development budgets have contributed to major pharmaceutical companies, their animal health divisions and our competitors focusing on small molecule therapies, reformulations and line extensions while overlooking mAbs as a development priority. In contrast, we are completely focused on biologics for companion animals.

 


    • Development and manufacturing costs. There is a perceived high cost associated with the development and manufacture of mAbs and therapeutic proteins at commercial scale. Our PETization platform is designed to develop mAb therapeutics cost-effectively.
    • Immunogenicity. Improperly designed biologics can induce a significant negative immune response, or immunogenicity. This is the body’s reaction to the identification of foreign material, resulting in the biologic being inactivated and cleared from the body, thereby diminishing or removing its therapeutic effect. Although mAb therapies are used to treat many diseases in humans, these drugs cannot be used routinely to treat animal disease since they will be recognized as foreign. PETization is designed to produce 100% species-specific mAbs that minimize the risk of immunogenicity.

Nexvet Biopharma

Ireland
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522 

Australia
Level 8, 31 Queen Street
Melbourne 3000
Victoria
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108

Email: info@nexvet.com

Get in Touch